ClinicalTrials.gg
CompletedNCT06995430Updated Nov 6, 2026Results posted

A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)

A Phase 3 interventional study of rMenB+OMV NZ vaccine in Meningitis, sponsored by GlaxoSmithKline. Completed at 17 sites in 4 countries. Open to participants aged 10 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Updated Nov 6, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
10 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Meningitis by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningitis · GlaxoSmithKline.

Enrollment
13th of 15
312 · median 704
Started
2025
the only one that year
Phase 3
10 of 16
none open now
Registered
16th of 16
by date

Among the 16 studies in Meningitis by GlaxoSmithKline, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 10 in phase 3, and was the 16th registered.

Meningitis

268 studies on the registry are indexed under Meningitis; 28 are open to participants now.

Browse Meningitis studies →

Open to participants now

None of the 16 studies in Meningitis by GlaxoSmithKline is open now. The open studies under Meningitis, anywhere →

Who these studies take

Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 10 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Meningitis by GlaxoSmithKline as a file.
02

Study summary

The main purpose of this study was to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focused on individuals who were first vaccinated with rMenB+OMV NZ as infants. The primary hypothesis was that a booster dose of the vaccine would elicit a stronger immune response in these primed individuals compared to those who had never received any group B meningococcal vaccine, referred to as 'naïve' participants.

03

Conditions studied

  • Meningitis

Browse trials for

Keywords

  • Meningitis
  • Booster dose
  • Bexsero
  • Immune response
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
10 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants were eligible to be included in the study only if all of the following criteria applied:

For primed group only:

  • Participated who were primed with rMenB + OMV NZ in only either 3+1 or 2+1 schedule during the first 2 years of life as confirmed by electronic or paper vaccination record.

OR

For naïve group only:

  • Electronic or paper vaccination record confirmed participant who has never received any group B meningococcal vaccine and is recruited in the same country as primed participants.

For all participants:

  • Participants and/or participants' parent(s)/ legally acceptable representative(s) (LAR[s]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the participant / parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
  • Written informed assent obtained from the participant (if applicable) along with informed consent from the participant's parent(s)/LAR(s) prior to performing any study specific procedure.

Note: For age 10-16 years, parents or LAR to give consent along with participants, based on country regulations for participants and for >16/18 to 20 years, participants give consent independent of parents/LARs, or as per local country regulations.

  • A male or female between, and including, 10 and 20 years of age at the time of the first study intervention administration.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral ovariectomy.
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate for 1 month prior to study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception during the entire study treatment period.

Exclusion criteria

Exclusion Criteria:

Participants were excluded from the study if any of the following criteria applied:

Medical conditions

  • Current or previous, confirmed or suspected disease caused by N. meningitidis.
  • Known exposure to an individual with laboratory confirmed N. meningitidis infection, within 60 days prior to enrollment.
  • History of any reaction or likely to be exacerbated by any component of the study intervention.
  • Medical conditions representing a to intramuscular vaccination and blood draws.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study intervention during the period beginning 30 days before the first dose of study intervention (Day -29 to Day 1), or their planned use during the study period.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.

    • Within 90 days prior to study intervention administration: for , this will mean prednisone equivalent >=20 milligram (mg)/day for adult participants or >=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.
    • Within 90 days prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives within 180 days prior to study intervention administration and/or planned use at any time up to the end of the study.

For primed group only:

  • Participants who received additional dose(s) of group B meningococcal vaccine other than 2+1 or 3+1 schedule prior to study intervention administration.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/vaccine/invasive medical device).

Other exclusion criteria

  • Pregnant or lactating female participant.
  • Any study personnel or their immediate dependents, family, or household member.
  • Child in care.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Primed group

    Participants who were primed with rMenB+OMV NZ vaccine in a 3 (2+1) doses or 4 (3+1) doses vaccination schedule during the first 2 years of life, received 1 dose of rMenB+OMV NZ vaccine at Day 1.

    Biological: rMenB+OMV NZ vaccine

  • Active comparator
    Naïve group

    Participants who never received any group B meningococcal vaccine previously, received 2 doses of rMenB+OMV NZ vaccine, one at Day 1 and one at Day 31.

    Biological: rMenB+OMV NZ vaccine

Interventions

  • BiologicalrMenB+OMV NZ vaccine

    Drug page: 4CMenB vaccine

    1 dose in the Primed group or 2 doses in the Naïve group.

    Also known as: Bexsero

06

What researchers measure

Primary outcomes

  1. Human Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric Mean Titers (GMTs) Against Each MenB Indicator Strain, and Between-group GMT Ratios at Day 31

    hSBA titers against each MenB indicator strain were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Day 31

Secondary outcomes

  1. Percentage of Participants With hSBA Titers Greater Than or Equal (>=) to 4 Against Each MenB Indicator Strain at Day 31

    The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Day 31

  2. Percentage of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Each MenB Indicator Strain at Day 31

    The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Day 31

  3. Percentage of Participants With >=4-fold Increase in hSBA Titers Against Each MenB Indicator Strain at Day 31 Relative to Day 1

    The percentage of participants with \>=4-fold increase in hSBA titers against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA. 4-fold increase in hSBA titers is defined as: * Post-vaccination hSBA titers \>= 8 for participants with pre-vaccination hSBA titers lower than (\<) 2; * Post-vaccination hSBA titers \>= 4 times the pre-vaccination hSBA titers for participants with pre-vaccination hSBA titers \>=2.

    Time frame: At Day 31 relative to Day 1

  4. hSBA Geometric Mean Ratios (GMRs) Against Each MenB Indicator Strain at Day 31 Compared to Baseline (Day 1)

    The immune response to the rMenB+OMV NZ vaccine against each MenB indicator strain was evaluated in terms of hSBA GMRs and expressed as within-group ratios of hSBA GMTs against each of the MenB indicator strains at Day 31 compared to Baseline (Day 1). The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Day 31 compared to Baseline (Day 1)

  5. Percentage of Participants With hSBA Titers >=4 Against Each MenB Indicator Strain at Baseline (Day 1)

    The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Baseline (Day 1)

  6. Percentage of Participants With hSBA Titers >=LLOQ Against Each Serogroup B Indicator Strain at Baseline (Day 1)

    The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Baseline (Day 1)

  7. hSBA Titers Expressed as GMTs Against Each MenB Indicator Strain at Baseline (Day 1)

    hSBA titers against each MenB indicator strains were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

    Time frame: At Baseline (Day 1)

  8. Number of Participants Reporting Any Solicited Administration Site Events

    The assessed solicited administration site events included administration site erythema (redness), swelling, pain and induration. Any = occurrence of the event regardless of intensity grade.

    Time frame: Within 7 days after the first vaccination occurring at Day 1

  9. Number of Participants Reporting Any Solicited Systemic Events

    The assessed solicited systemic events included headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), nausea and fever (pyrexia). Fever is defined as body temperature \>=38.0°C/100.4°F. The preferred location for measuring temperature in this study was axillary. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.

    Time frame: Within 7 days after the first vaccination occurring at Day 1

  10. Number of Participants Reporting Any Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of the intensity grade or relation to the study vaccination.

    Time frame: Within 31 days after the first vaccination occurring at Day 1

  11. Number of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis)

    AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. The assessed AESI in this study was arthritis.

    Time frame: From Day 1 to Day 31

  12. Number of Participants Reporting Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, in an abnormal pregnancy outcome, or in other situations that were considered serious per medical or scientific judgment.

    Time frame: From Day 1 to Day 31

  13. Number of Participants Reporting AEs Leading to Withdrawal

    AEs leading to withdrawal are defined as AEs due to which the participant is considered to have withdrawn from the study as no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact.

    Time frame: From Day 1 to Day 31

07

Results

Posted Nov 6, 2026

Participant flow

The study population consisted of eligible participants who were previously primed with rMenB+OMV NZ vaccine in studies V72\_28 (EudraCT number: 2010-021528-81), V72\_P12E1 (EudraCT number: 2009-011676-30), V72\_P13E1 (EudraCT number: 2008-006301-17) or in routine practice during the first 2 years of life, and of vaccine-naïve participants, who never received any group B meningococcal vaccine previously.

Participant flow — Overall Study
MilestonePrimed GroupNaïve Group
Started23478
Completed23378
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryHuman Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric Mean Titers (GMTs) Against Each MenB Indicator Strain, and Between-group GMT Ratios at Day 31

hSBA titers against each MenB indicator strain were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Day 31
Reported as:
Geometric mean · Titers
Human Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric Mean Titers (GMTs) Against Each MenB Indicator Strain, and Between-group GMT Ratios at Day 31
TitersPrimed GroupNaïve Group
fHbp24.2 (20.4 to 28.8)6.2 (4.7 to 8.2)
NadA844.9 (704.5 to 1013.3)54.3 (40.0 to 73.8)
NHBA14.0 (12.1 to 16.4)10.4 (8.1 to 13.3)
PorA10.0 (8.4 to 11.9)5.7 (4.2 to 7.6)
Statistical analysis
  • Primed Group vs Naïve Group · ANCOVA · Group gmt ratio: 3.89 · 95% CI 2.78 to 5.46The ratio of GMTs (Primed/Naïve) and the corresponding CI is constructed by exponentiating the mean difference and the confidence limits in log10 (titer), using ANCOVA with baseline, age and country included as independent variables.
  • Primed Group vs Naïve Group · ANCOVA · Group gmt ratio: 15.55 · 95% CI 10.72 to 22.55The ratio of GMTs (Primed/Naïve) and the corresponding CI is constructed by exponentiating the mean difference and the confidence limits in log10 (titer), using ANCOVA with baseline, age and country included as independent variables.
  • Primed Group vs Naïve Group · ANCOVA · Group gmt ratio: 1.35 · 95% CI 1.004 to 1.82The ratio of GMTs (Primed/Naïve) and the corresponding CI is constructed by exponentiating the mean difference and the confidence limits in log10 (titer), using ANCOVA with baseline, age and country included as independent variables.
  • Primed Group vs Naïve Group · ANCOVA · Group gmt ratio: 1.77 · 95% CI 1.25 to 2.50The ratio of GMTs (Primed/Naïve) and the corresponding CI is constructed by exponentiating the mean difference and the confidence limits in log10 (titer), using ANCOVA with baseline, age and country included as independent variables.
SecondaryPercentage of Participants With hSBA Titers Greater Than or Equal (>=) to 4 Against Each MenB Indicator Strain at Day 31

The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Day 31
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers Greater Than or Equal (>=) to 4 Against Each MenB Indicator Strain at Day 31
Percentage of participantsPrimed GroupNaïve Group
fHbp87.9 (83.0 to 91.8)64.1 (52.4 to 74.7)
NadA99.1 (96.9 to 99.9)87.2 (77.7 to 93.7)
NHBA85.7 (80.4 to 89.9)56.6 (44.7 to 67.9)
PorA70.7 (64.4 to 76.5)41.6 (30.4 to 53.4)
SecondaryPercentage of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Each MenB Indicator Strain at Day 31

The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Day 31
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >= Lower Limit of Quantitation (LLOQ) Against Each MenB Indicator Strain at Day 31
Percentage of participantsPrimed GroupNaïve Group
fHbp86.2 (81.1 to 90.4)56.4 (44.7 to 67.6)
NadA99.1 (96.9 to 99.9)71.8 (60.5 to 81.4)
NHBA81.3 (75.7 to 86.1)51.3 (39.6 to 63.0)
PorA62.1 (55.5 to 68.3)40.3 (29.2 to 52.1)
SecondaryPercentage of Participants With >=4-fold Increase in hSBA Titers Against Each MenB Indicator Strain at Day 31 Relative to Day 1

The percentage of participants with \>=4-fold increase in hSBA titers against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA. 4-fold increase in hSBA titers is defined as: * Post-vaccination hSBA titers \>= 8 for participants with pre-vaccination hSBA titers lower than (\<) 2; * Post-vaccination hSBA titers \>= 4 times the pre-vaccination hSBA titers for participants with pre-vaccination hSBA titers \>=2.

Time frame:
At Day 31 relative to Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With >=4-fold Increase in hSBA Titers Against Each MenB Indicator Strain at Day 31 Relative to Day 1
Percentage of participantsPrimed GroupNaïve Group
fHbp74.9 (68.8 to 80.3)28.6 (18.8 to 40.0)
NadA98.3 (95.6 to 99.5)68.8 (57.3 to 78.9)
NHBA54.9 (48.0 to 61.7)29.3 (19.4 to 41.0)
PorA51.5 (44.9 to 58.1)30.3 (20.2 to 41.9)
SecondaryhSBA Geometric Mean Ratios (GMRs) Against Each MenB Indicator Strain at Day 31 Compared to Baseline (Day 1)

The immune response to the rMenB+OMV NZ vaccine against each MenB indicator strain was evaluated in terms of hSBA GMRs and expressed as within-group ratios of hSBA GMTs against each of the MenB indicator strains at Day 31 compared to Baseline (Day 1). The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Day 31 compared to Baseline (Day 1)
Reported as:
Geometric mean · Ratio
hSBA Geometric Mean Ratios (GMRs) Against Each MenB Indicator Strain at Day 31 Compared to Baseline (Day 1)
RatioPrimed GroupNaïve Group
fHbp9.69 (8.15 to 11.52)2.38 (1.79 to 3.16)
NadA90.19 (74.47 to 109.22)8.67 (6.34 to 11.87)
NHBA4.03 (3.43 to 4.74)2.82 (2.16 to 3.66)
PorA4.31 (3.61 to 5.14)2.43 (1.81 to 3.25)
SecondaryPercentage of Participants With hSBA Titers >=4 Against Each MenB Indicator Strain at Baseline (Day 1)

The percentage of participants with hSBA titers \>=4 against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >=4 Against Each MenB Indicator Strain at Baseline (Day 1)
Percentage of participantsPrimed GroupNaïve Group
fHbp15.9 (11.4 to 21.2)16.9 (9.3 to 27.1)
NadA57.3 (50.7 to 63.7)23.4 (14.5 to 34.4)
NHBA27.4 (21.6 to 33.8)22.1 (13.4 to 33.0)
PorA7.7 (4.6 to 11.9)5.2 (1.4 to 12.8)
SecondaryPercentage of Participants With hSBA Titers >=LLOQ Against Each Serogroup B Indicator Strain at Baseline (Day 1)

The percentage of participants with hSBA titers \>=LLOQ value against each MenB indicator strain is reported. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Baseline (Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >=LLOQ Against Each Serogroup B Indicator Strain at Baseline (Day 1)
Percentage of participantsPrimed GroupNaïve Group
fHbp11.6 (7.8 to 16.4)16.9 (9.3 to 27.1)
NadA43.6 (37.1 to 50.2)13.0 (6.4 to 22.6)
NHBA22.8 (17.4 to 29.0)20.8 (12.4 to 31.5)
PorA6.4 (3.6 to 10.4)5.2 (1.4 to 12.8)
SecondaryhSBA Titers Expressed as GMTs Against Each MenB Indicator Strain at Baseline (Day 1)

hSBA titers against each MenB indicator strains were determined by human serum bactericidal assay and expressed as GMTs. The assessed MenB indicator strains were: fHbp, NadA, NHBA and PorA.

Time frame:
At Baseline (Day 1)
Reported as:
Geometric mean · Titers
hSBA Titers Expressed as GMTs Against Each MenB Indicator Strain at Baseline (Day 1)
TitersPrimed GroupNaïve Group
fHbp2.5 (2.3 to 2.7)2.8 (2.4 to 3.2)
NadA10.8 (9.2 to 12.6)4.3 (3.3 to 5.5)
NHBA3.4 (2.9 to 4.0)3.9 (3.0 to 5.0)
PorA2.3 (2.2 to 2.5)2.4 (2.1 to 2.7)
SecondaryNumber of Participants Reporting Any Solicited Administration Site Events

The assessed solicited administration site events included administration site erythema (redness), swelling, pain and induration. Any = occurrence of the event regardless of intensity grade.

Time frame:
Within 7 days after the first vaccination occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events
ParticipantsPrimed GroupNaïve Group
Erythema (Redness)349
Swelling4412
Pain23077
Induration4410
SecondaryNumber of Participants Reporting Any Solicited Systemic Events

The assessed solicited systemic events included headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness), nausea and fever (pyrexia). Fever is defined as body temperature \>=38.0°C/100.4°F. The preferred location for measuring temperature in this study was axillary. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination.

Time frame:
Within 7 days after the first vaccination occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events
ParticipantsPrimed GroupNaïve Group
Headache12839
Myalgia (Muscle pain)16456
Arthralgia (Joint pain)7930
Fatigue (Tiredness)18058
Nausea4917
Fever (Pyrexia)61
SecondaryNumber of Participants Reporting Any Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Any = occurrence of the event regardless of the intensity grade or relation to the study vaccination.

Time frame:
Within 31 days after the first vaccination occurring at Day 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)
ParticipantsPrimed GroupNaïve Group
Number of Participants Reporting Any Unsolicited Adverse Events (AEs)4911
SecondaryNumber of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis)

AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it. The assessed AESI in this study was arthritis.

Time frame:
From Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis)
ParticipantsPrimed GroupNaïve Group
Number of Participants Reporting an Adverse Event of Special Interest (AESI) (Arthritis)00
SecondaryNumber of Participants Reporting Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, in an abnormal pregnancy outcome, or in other situations that were considered serious per medical or scientific judgment.

Time frame:
From Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs)
ParticipantsPrimed GroupNaïve Group
Number of Participants Reporting Serious Adverse Events (SAEs)10
SecondaryNumber of Participants Reporting AEs Leading to Withdrawal

AEs leading to withdrawal are defined as AEs due to which the participant is considered to have withdrawn from the study as no new study procedure has been performed or no new information has been collected for them since the date of withdrawal/last contact.

Time frame:
From Day 1 to Day 31
Reported as:
Count of participants · Participants
Number of Participants Reporting AEs Leading to Withdrawal
ParticipantsPrimed GroupNaïve Group
Number of Participants Reporting AEs Leading to Withdrawal00

Adverse events

Collected over Solicited AEs: within 7 days after the first vaccination. Unsolicited AEs: within 31 days after the first vaccination. All-cause mortality, all SAEs, AEs leading to withdrawal, AESI (arthritis): from Day 1 to Day 31.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primed Group0/234 (0%)1/234 (0.4%)233/234 (99.6%)
Naïve Group0/78 (0%)0/78 (0%)77/78 (98.7%)
Most frequent serious events
Most frequent serious events
EventPrimed GroupNaïve Group
AppendicitisInfections and infestations1/2340/78
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPrimed GroupNaïve Group
Administration site painGeneral disorders230/23477/78
FatigueGeneral disorders180/23458/78
MyalgiaMusculoskeletal and connective tissue disorders164/23456/78
HeadacheNervous system disorders129/23439/78
ArthralgiaMusculoskeletal and connective tissue disorders79/23430/78
NauseaGastrointestinal disorders49/23417/78
Administration site indurationGeneral disorders44/23410/78
Administration site swellingGeneral disorders44/23412/78
Administration site rednessGeneral disorders34/2349/78
PyrexiaGeneral disorders8/2341/78

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Primed GroupNaïve GroupTotal
Mean15.3 ± 2.214.8 ± 2.615.2 ± 2.3
Sex: Female, Male
Sex: Female, Male(Participants)Primed GroupNaïve GroupTotal
Female12644170
Male10834142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Primed GroupNaïve GroupTotal
Black or African American011
Multiple123
Not reported101
White23275307
08

Study locations

17 sites
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinäjoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Florence, 50139, Italy
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Novara, 28100, Italy
  • GSK Investigational Site
    Santiago de Compostela, 15701, Spain
  • GSK Investigational Site
    Seville, 41014, Spain
  • GSK Investigational Site
    Bristol, BS2 8BJ, United Kingdom
  • GSK Investigational Site
    London, SW17 0RE, United Kingdom
  • GSK Investigational Site
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 19 phase 3 interventional studies under Meningitis, half reached primary completion within 15 months of starting (the median); a quarter within 7 and three quarters within 28. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
Jul 7, 2025
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Primary completion
Dec 8, 2025→Dec 15, 2025
Nov 6, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants arewere eligible to be included in the study only if all of the following criteria applyapplied:
Exclusion criteria
  • EditedParticipants arewere excluded from the study if any of the following criteria applyapplied:
  • EditedWithin 90 days prior to study intervention administration: for corticosteroids, this will mean prednisone equivalent ≥>=20 milligram (mg)/day for adult participants or >= 0.5 mg/kg/day with maximum of 20 milligram (mg)/day for pediatric participants. Inhaled and topical steroids are allowed.
Nov 6, 2026
Interventions
Arm changed Naive group→Naïve group
Nov 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedHuman Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric mean titersMean Titers (GMTs) ratio against eachAgainst Each MenB indicator strainIndicator Strain, and Between-group GMT Ratios at Day 31Time frame: At Day 31
Nov 6, 2026
Documents
Secondary outcomes
11 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedNumberPercentage of participants withParticipants With hSBA titers greater thanTiters Greater Than or equalEqual (>=) to pre-defined limit of detection against each4 Against Each MenB indicator strainIndicator Strain at Day 31Time frame: At Day 31
  • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= lower limitLower Limit of quantificationQuantitation (LLOQ) against eachAgainst Each MenB indicator strainIndicator Strain at Day 31Time frame: At Day 31
  • EditedNumberPercentage of participants with fourParticipants With >=4-fold increaseIncrease in hSBA titersTiters Against Each MenB Indicator Strain at Day 31 Relative to Day 1Time frame: At Day 31 → At Day 31 relative to Day 1
  • EditedhSBA Titers Expressed as GMTs against eachAgainst Each MenB indicator strainIndicator Strain at Baseline (Day 1)Time frame: At Day 31 compared to Day 1 → At Baseline (Day 1)
  • EditedhSBA Geometric Mean Ratios (GMRs) against eachAgainst Each MenB indicator strainIndicator Strain at Day 31 Compared to Baseline (Day 1)Time frame: At Day 31 compared to Day 1 → At Day 31 compared to Baseline (Day 1)
  • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= to pre-defined limit of detection against each4 Against Each MenB indicator strainIndicator Strain at Baseline (Day 1)Time frame: At Day 1 → At Baseline (Day 1)
  • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= LLOQ against each MenB indicator strainAgainst Each Serogroup B Indicator Strain at Baseline (Day 1)Time frame: At Day 1 → At Baseline (Day 1)
  • EditedNumber of participants with solicited administration site eventsParticipants Reporting Any Solicited Administration Site EventsTime frame: Day 1 (day of injection) to Day 7 → Within 7 days after the first vaccination occurring at Day 1
  • EditedNumber of participants with solicited systemic eventsParticipants Reporting Any Solicited Systemic EventsTime frame: Day 1 (day of injection) to Day 7 → Within 7 days after the first vaccination occurring at Day 1
  • EditedNumber of participants with any unsolicited adverse eventsParticipants Reporting Any Unsolicited Adverse Events (AEs)Time frame: Day 1 (day of injection) to Day 31 → Within 31 days after the first vaccination occurring at Day 1
  • EditedNumber of participants with adverse eventsParticipants Reporting an Adverse Event of special interestSpecial Interest (AESI): arthritis, serious adverse events (SAEsArthritis), AEs leading to withdrawalTime frame: Day 1 to Day 31 (throughout the study period) → From Day 1 to Day 31
  • AddedNumber of Participants Reporting Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 31
  • AddedNumber of Participants Reporting AEs Leading to WithdrawalTime frame: From Day 1 to Day 31
  • RemovedhSBA GMTs against each MenB indicator strainTime frame: At Day 1
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    Primary completion Dec 8, 2025→Dec 15, 2025
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants arewere eligible to be included in the study only if all of the following criteria applyapplied:
    Exclusion criteria
    • EditedParticipants arewere excluded from the study if any of the following criteria applyapplied:
    • EditedWithin 90 days prior to study intervention administration: for corticosteroids, this will mean prednisone equivalent ≥>=20 milligram (mg)/day for adult participants or >= 0.5 mg/kg/day with maximum of 20 milligram (mg)/day for pediatric participants. Inhaled and topical steroids are allowed.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedHuman Serum Bactericidal Assay (hSBA) Titers Expressed as Geometric mean titersMean Titers (GMTs) ratio against eachAgainst Each MenB indicator strainIndicator Strain, and Between-group GMT Ratios at Day 31Time frame: At Day 31
    Secondary outcomes 11 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedNumberPercentage of participants withParticipants With hSBA titers greater thanTiters Greater Than or equalEqual (>=) to pre-defined limit of detection against each4 Against Each MenB indicator strainIndicator Strain at Day 31Time frame: At Day 31
    • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= lower limitLower Limit of quantificationQuantitation (LLOQ) against eachAgainst Each MenB indicator strainIndicator Strain at Day 31Time frame: At Day 31
    • EditedNumberPercentage of participants with fourParticipants With >=4-fold increaseIncrease in hSBA titersTiters Against Each MenB Indicator Strain at Day 31 Relative to Day 1Time frame: At Day 31 → At Day 31 relative to Day 1
    • EditedhSBA Titers Expressed as GMTs against eachAgainst Each MenB indicator strainIndicator Strain at Baseline (Day 1)Time frame: At Day 31 compared to Day 1 → At Baseline (Day 1)
    • EditedhSBA Geometric Mean Ratios (GMRs) against eachAgainst Each MenB indicator strainIndicator Strain at Day 31 Compared to Baseline (Day 1)Time frame: At Day 31 compared to Day 1 → At Day 31 compared to Baseline (Day 1)
    • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= to pre-defined limit of detection against each4 Against Each MenB indicator strainIndicator Strain at Baseline (Day 1)Time frame: At Day 1 → At Baseline (Day 1)
    • EditedNumberPercentage of participants withParticipants With hSBA titersTiters >= LLOQ against each MenB indicator strainAgainst Each Serogroup B Indicator Strain at Baseline (Day 1)Time frame: At Day 1 → At Baseline (Day 1)
    • EditedNumber of participants with solicited administration site eventsParticipants Reporting Any Solicited Administration Site EventsTime frame: Day 1 (day of injection) to Day 7 → Within 7 days after the first vaccination occurring at Day 1
    • EditedNumber of participants with solicited systemic eventsParticipants Reporting Any Solicited Systemic EventsTime frame: Day 1 (day of injection) to Day 7 → Within 7 days after the first vaccination occurring at Day 1
    • EditedNumber of participants with any unsolicited adverse eventsParticipants Reporting Any Unsolicited Adverse Events (AEs)Time frame: Day 1 (day of injection) to Day 31 → Within 31 days after the first vaccination occurring at Day 1
    • EditedNumber of participants with adverse eventsParticipants Reporting an Adverse Event of special interestSpecial Interest (AESI): arthritis, serious adverse events (SAEsArthritis), AEs leading to withdrawalTime frame: Day 1 to Day 31 (throughout the study period) → From Day 1 to Day 31
    • AddedNumber of Participants Reporting Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 31
    • AddedNumber of Participants Reporting AEs Leading to WithdrawalTime frame: From Day 1 to Day 31
    • RemovedhSBA GMTs against each MenB indicator strainTime frame: At Day 1
    Interventions Arm changed Naive group→Naïve group
    + 4 other changes: identifiers, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06995430
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jul 7, 2025
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion